NC
RXRX icon

Nehal Chopra’s Recursion Pharmaceuticals RXRX Stock Holding History

Nehal Chopra’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-35,069
Closed -$807K – 95
2021
Q3 		$807K Sell
35,069
-74,931
-68% -$2.12M 0.1% 76
2021
Q2 		$4.01M Buy
+110,000
New +$3.26M 0.35% 59

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $17.2M AUM 22.94% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Nehal Chopra's RXRX Position: Q4 2021 in Review

Nehal Chopra sold out of Recursion Pharmaceuticals (RXRX) in Q4 2021, closing a stake of 35,069 shares — an estimated $807K sold.

Nehal Chopra first reported a position in RXRX in Q2 2021 and held it in 2 quarters. The position peaked at $4.01M in Q2 2021. 126 funds tracked by Wall St. Rank hold RXRX as of Q4 2021.

  • Nehal Chopra reported no remaining Recursion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Nehal Chopra sold 35,069 Recursion Pharmaceuticals shares in Q4 2021, an estimated $807K.
  • Nehal Chopra first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Nehal Chopra's Recursion Pharmaceuticals position peaked at $4.01M in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2021.

Based on Ratan Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.